Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?

Lipids in Health and Disease

Volumn 9, Issue , 2010, Pages

  Bays, Harold ^a   Conard, Scott ^b   Leiter, Lawrence A ^c   Bird, Steven ^d   Jensen, Erin ^d   Hanson, Mary E ^d   Shah, Arvind ^d   Tershakovec, Andrew M ^d  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^b Medical Edge Healthcare Group   (United States)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; CHOLESTEROL; EZETIMIBE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONHIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; AZETIDINE DERIVATIVE; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY RISK; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARTICLE SIZE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; MIDDLE AGED;

AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; FEMALE; HEPTANOIC ACIDS; HUMANS; MALE; MIDDLE AGED; PYRROLES;

EID: 78649465611     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-9-136     Document Type: Article

References (41)

1. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. CP Cannon E Braunwald CH McCabe DJ Rader JL Rouleau R Belder SV Joyal KA Hill MA Pfeffer AM Skene, N Engl J Med 2004 350 1495 1504 10.1056/NEJMoa040583 15007110
2. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. JC LaRosa SM Grundy DD Waters C Shear P Barter JC Fruchart AM Gotto H Greten JJ Kastelein J Shepherd,, et al. N Engl J Med 2005 352 1425 1435 10.1056/NEJMoa050461 15755765
3. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. TR Pedersen O Faergeman JJ Kastelein AG Olsson MJ Tikkanen I Holme ML Larsen FS Bendiksen C Lindahl M Szarek,, et al. JAMA 2005 294 2437 2445 10.1001/jama.294.19.2437 16287954
4. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. E Ingelsson EJ Schaefer JH Contois JR McNamara L Sullivan MJ Keyes MJ Pencina C Schoonmaker PW Wilson RB D'Agostino,, et al. JAMA 2007 298 776 785 10.1001/jama.298.7.776 17699011
5. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease. JO Mudd BA Borlaug PV Johnston BG Kral R Rouf RS Blumenthal PO Kwiterovich Jr, J Am Coll Cardiol 2007 50 1735 1741 10.1016/j.jacc.2007.07.045 17964036
6. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. K El Harchaoui WA van der Steeg ES Stroes JA Kuivenhoven JD Otvos NJ Wareham BA Hutten JJ Kastelein KT Khaw SM Boekholdt, J Am Coll Cardiol 2007 49 547 553 10.1016/j.jacc.2006.09.043 17276177
7. The characterization of a discrete series of low density lipoproteins in the disease, hyper-pre-beta-lipoproteinemia. Implications relating to the structure of plasma lipoproteins. MG Hammond WR Fisher, J Biol Chem 1971 246 5454 5465 4999356
8. Does low-density lipoprotein size add to atherogenic particle number in predicting the risk of fatal myocardial infarction? I Jungner AD Sniderman C Furberg AH Aastveit I Holme G Walldius, Am J Cardiol 2006 97 943 946 10.1016/j.amjcard.2005.10.062 16563891
9. Cholesterol profile measurement by vertical auto profile method. KR Kulkarni, Clin Lab Med 2006 26 787 802 10.1016/j.cll.2006.07.004 17110240
10. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. DS Freedman JD Otvos EJ Jeyarajah JJ Barboriak AJ Anderson JA Walker, Arterioscler Thromb Vasc Biol 1998 18 1046 1053 9672064
11. The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. B Lamarche I Lemieux JP Despres, Diabetes Metab 1999 25 199 211 10499189
12. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression. WJ Mack RM Krauss HN Hodis, Arterioscler Thromb Vasc Biol 1996 16 697 704 8963728
13. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. RS Rosenson JD Otvos DS Freedman, Am J Cardiol 2002 90 89 94 10.1016/S0002-9149(02)02427-X 12106834
14. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. MJ Stampfer RM Krauss J Ma PJ Blanche LG Holl FM Sacks CH Hennekens, JAMA 1996 276 882 888 10.1001/jama.276.11.882 8782637
15. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. HB Rubins SJ Robins D Collins CL Fye JW Anderson MB Elam FH Faas E Linares EJ Schaefer G Schectman,, et al. N Engl J Med 1999 341 410 8 10.1056/NEJM199908053410604 10438259
16. High-density lipoprotein particle size and concentration and coronary risk. K El Harchaoui BJ Arsenault R Franssen JP Despres GK Hovingh ES Stroes JD Otvos NJ Wareham JJ Kastelein KT Khaw,, et al. Ann Intern Med 2009 150 84 93 19153411
17. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. F Nigon P Lesnik M Rouis MJ Chapman, J Lipid Res 1991 32 1741 1753 1770294
18. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. V Anber BA Griffin M McConnell CJ Packard J Shepherd, Atherosclerosis 1996 124 261 271 10.1016/0021-9150(96)05842-X 8830938
19. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. DL Tribble LG Holl PD Wood RM Krauss, Atherosclerosis 1992 93 189 199 10.1016/0021-9150(92)90255-F 1590824
20. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. JG Robinson B Smith N Maheshwari H Schrott, J Am Coll Cardiol 2005 46 1855 1862 10.1016/j.jacc.2005.05.085 16286171
21. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. LA Leiter H Bays S Conard S Bird J Rubino ME Hanson JE Tomassini AM Tershakovec, Am J Cardiol 2008 102 1495 1501 10.1016/j.amjcard.2008.09.076 19026303
22. Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects. MH Davidson HE Bays E Stein KC Maki RA Shalwitz R Doyle, Clin Cardiol 2006 29 268 273 10.1002/clc.4960290609 16796078
23. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Expert panel on detection evaluation and treatment of high blood cholesterol in adults, JAMA 2001 285 2486 2497 10.1001/jama.285.19.2486 11368702
24. Quantification of cholesterol in all lipoprotein classes by the VAP-II method. KR Kulkarni DW Garber SM Marcovina JP Segrest, J Lipid Res 1994 35 159 168 8138718
25. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Y Benjamini Y Hochberg, J R Statist Soc B (Methodological) 1995 57 289 300
26. Effects of atorvastatin on nuclear magnetic resonance-defined lipoprotein subclasses and inflammatory markers in patients with hypercholesterolemia. K Ikewaki Y Terao H Ozasa Y Nakada J Tohyama Y Inoue M Yoshimura, J Atheroscler Thromb 2009 16 51 56 19261998
27. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. The Diabetes Atorvastatin Lipid Intervention (DALI) Study Group, Diabetes Care 2001 24 1335 1341 10.2337/diacare.24.8.1335 11473066
28. Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy. SL Airan-Javia RL Wolf ML Wolfe M Tadesse E Mohler MP Reilly, Am Heart J 2009 157 687 688 10.1016/j.ahj.2009.01.001 19332196
29. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. KC Maki JM McKenney MS Reeves BC Lubin MR Dicklin, Am J Cardiol 2008 102 429 433 10.1016/j.amjcard.2008.03.078 18678300
30. The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates. M Rizzo K Berneis, Cur Med Res Opin 2007 23 1103 1111 10.1185/030079907X187892 (Pubitemid 46799594)
31. Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. M Farnier E Roth B Gil-Extremera GF Mendez G Macdonell C Hamlin I Perevozskaya MJ Davies D Kush YB Mitchel, Am Heart J 2007 153 335 338 10.1016/j.ahj.2006.10.031 17239698
32. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia. DL Tribble M Farnier G Macdonell I Perevozskaya MJ Davies B Gumbiner TA Musliner, Metabolism 2008 57 796 801 10.1016/j.metabol.2008.01.026 18502262
33. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. M Kalogirou V Tsimihodimos I Gazi T Filippatos V Saougos AD Tselepis DP Mikhailidis M Elisaf, Curr Med Res Opin 2007 23 1169 1176 10.1185/030079907X188062 17519084
34. Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia. JE Tomassini T Mazzone RB Goldberg JR Guyton RS Weinstock A Polis E Jensen AM Tershakovec, Diabetes Obes Metab 2009 11 855 864 10.1111/j.1463-1326.2009.01061. x 19508464
35. Differential effects of fluvastatin alone or in combination with ezetimibe on lipoprotein subfractions in patients at high risk of coronary events. T Stojakovic A de Campo H Scharnagl H Sourij I Schmolzer TC Wascher W Marz, Eur J Clin Invest 2010 40 187 194 10.1111/j.1365-2362.2009.02249.x 20067513
36. Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. K Berneis M Rizzo HK Berthold GA Spinas W Krone I Gouni-Berthold, Eur Heart J 2010 31 1633 1639 10.1093/eurheartj/ehq181 20525999
37. Ezetimibe: cholesterol lowering and beyond. HE Bays D Neff JE Tomassini AM Tershakovec, Expert Rev Cardiovasc Ther 2008 6 447 470 10.1586/14779072.6.4. 447 18402536
38. Small, dense low-density lipoprotein: risk or myth? NA Le, Curr Atheroscler Rep 2003 5 22 28 10.1007/s11883-003-0064-4 12562538
39. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. CP Cannon BA Steinberg SA Murphy JL Mega E Braunwald, J Am Coll Cardiol 2006 48 438 445 10.1016/j.jacc.2006.04.070 16875966 (Pubitemid 44109954)
40. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? RJ Simes IC Marschner D Hunt D Colquhoun D Sullivan RA Stewart W Hague A Keech P Thompson H White,, et al. Circulation 2002 105 1162 1169 10.1161/hc1002.105136 11889008
41. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). AM Gotto Jr E Whitney EA Stein DR Shapiro M Clearfield S Weis JY Jou A Langendorfer PA Beere DJ Watson,, et al. Circulation 2000 101 477 484 10662743